

Atty Docket No: US-CH02.02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:))	er 30, 2002	A.G.I
Ma et	al.	,))		12/17/0
Serial	No.: 09/801,115) Group Art Unit:	1647	•
Filed:	March 7, 2001)	get E. Bunner	
For:	Chemokine-Like Factors (CKLFs) With Chemotactic And Hematopoietic Stimulating Activities)))	RECE	
	TRANSMITTAL OF MISSI FOR PREVIOUSLY INFORMATION DISCLOS	TECH CENTER		

Commissioner for Patents **Box Patent Application** Washington, D.C. 20231

Sir:

Applicants respectfully submit the copies of two references (No. AG and AK) which the Examiner maintains were missing from the original Information Disclosure Statement submitted on July 6, 2001, and an English abstract of reference No. AE (CN 1202906) and EP 0860446A1 which is the equivalent of CN 1202906.

CERTIFICATE OF MAILING BY EXPRESS MAIL
Express Mail mailing label numberEK950433940US
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Box PATENT APPLICATION, Commissioner for Patents, Washington, DC 20231.
on
Typed or printed name of person signing this certificate Yi Li
Signature 6

The undersigned states that the references being provided are the same ones that were cited to the Patent and Trademark Office before the mailing date of a first Office action on the merits of the above-referenced patent application and are being provided to the Examiner within the period of time for response to the notice of missing references. Accordingly, Applicants maintain that in accordance with 37 CFR 1.97(b)(3) no fee is required to be paid upon the filing of this Information Disclosure Statement.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

A PTO 1449 Form listing these missing references, along with copies of the references, is enclosed. The Examiner is respectfully requested to make of record these references.

Respectfully submitted,

Date: 11/30/2002

y: VIII

Registration No. 44,211
Agent for Applicant

Telephone: (786) 242-9349

Please address all correspondence to:

CUSPA Technology Law Associates 11820 SW 107 Ave. Miami, FL 33176



TECH CENTER 1600/2900 1 of 1

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office			Attorney Docket No. US-CH02,02		Serial No. 09/801,115			
			Applicant: Ma, et al.					
			Filing Date: 3/7/2001		Group: 1647			
			U. S. PATE	NT DOCUMENTS		•		
Examiner Initial	Ref	Document Number	Date	Name	Class	Sub- Class	Filing Da Appropr	
	<u> </u>							
	<u> </u>							
	<u> </u>							
	Т	Ţ	FOREIGN PA	TENT DOCUMENTS	1	<u> </u>	Υ	
	Ref	Document Number	Date	Country	Class	Sub- Class	Translation	
							Yes	No
	AE	CN 1202906	12/23/1998	China			Abstra	ct
		EP 0860446A1, equivalent of CN 1202906					English documer	
	_							
	<u> </u>							
				uthor, Title, Date, Perti			_	
	AG	Brantschen et al. 1989, "Differential Expression of Cytokine mRNAs in Human Cell Lines", Lymphkine Research, 2(3) 163-72.						
	AK	Marshall et al., 199 (2): 120.	8 "HGS launch	es "first" genomics produ	ct in clinic",	Nature B	iotechnolo	ogy, 16
			<u>.</u>					
EXAMINER				DATE CONSIDERED				
*EXAMINE through citat applicant.	R: Initia	l if citations considere t in conformance and	ed, whether or not considered	ot citation is in conforma I. Include copy of this for	tion with MF rm with next	PEP 609; commur	Draw line ication to	